Shanghai Chemo Wanbang Biopharma Co.,LTD is a joint venture between Jiangsu Wanbang Biochemical Pharmaceutical Group Co., LTD, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., LTD, and Spanish Chemo Pharmaceutical Group. It was established on November 19, 2008 and the registered capital was 153 million yuan RMB.

Fosun Pharma, founded in 1994, is a leading health care group in China. Its business covers the whole industrial production chain, including drug manufacturing,research and development, health care service, medical instruments and medicaldiagnosis, pharmaceutical distribution and retail.

Jiangsu Wanbang Biochemical Pharmaceutical Group Co., LTD. is a core member of Shanghai Fosun Pharmaceutical (group)Co., LTD. It has a first-class R&D and production base for prokaryotic and eukaryotic cells genetic engineering drugs, also in a leading position of developing recombinant protein drugs including recombinant humaninsulin anditsanalogues, treatment cytokines and so on. Their pharmaceutical products include bulk pharmaceutical chemicals and their preparations, biochemical drugs and biological products,proprietary Chinese medicine, etc.

Chemo Industrial is part of the Spanish multinational, CHEMO, a group with a strong foundation and a firm investor commitment to all our business activity areas. With 40 years’ of experience, CHEMO is a group that aims to sustain and improve people’s health and well being, and has a presence at every echelon of the chemical-pharmaceutical industry. Its activities are carried outthrough three synergistic business areas: industrial, branded andbiotechnology. The CHEMO group has a presence in more than 40 countries in Europe, the Americas, Asia and Africa, and is backed up by a network of more than 6,000 professionals.

Chemo Wanbang, ahigh-tech enterprise in Shanghai, has advanced production technology andequipment, and the company mainly features biotechnology drugs and anti-tumordrugs. In order to adapt to the development of globalization, and to further expand production capacity, the Fosun Pharma Group and Spain CHEMO group signeda strategic cooperation framework agreement in August 2010, and set up a new GMP certified production base for CHEMO recombinant protein drugs and sterileinjections (antineoplastic agent) in the Jinshan industrial park, covering anarea of 80 mu. Three hundred twenty million yuan RMB has been invested in this new plant, which includes one recombinant protein drug workshop, one biological production workshop and one anti-tumor drug preparation workshop and one quality control and R&D center.

At the end of 2013, the construction of this plant in Jinshan was accomplished in accordance with the schedule and in the same year the plant successfully passed the new GMP certification of the State Food and Drug Administration of China. In January 2014, the company moved to Jinshan industrial park, and the production andresearch base was officially put into use.

The main products of the company include Recombinant Human Erythropoietin, which has a constantly high market share, Recombinant Human Interferon γ for Injection,Eluzer, and Cicleadon. From 2010 to 2015, the annual compound growth rate of the company's sales revenues is above 30%, and the compound growth rate of netprofit is above 40%.

Focusing on pharmaceutical innovation, effectiveness and safety, our company will continue working on the new drug research and development in the field of tumor treatment. Our company strive to develop new drugs with independent intellectual property rights and with market competitiveness. We are aiming to become a leading biopharmaceutical company in China specialized in anti-cancer drugs.